

Original Article

# Association Between Serum Uric Acid Level and Metabolic Syndrome

Ju-Mi Lee<sup>1</sup>, Hyeon Chang Kim<sup>1,3</sup>, Hye Min Cho<sup>1</sup>, Sun Min Oh<sup>1</sup>, Dong Phil Choi<sup>1</sup>, Il Suh<sup>1</sup>

<sup>1</sup>Department of Preventive Medicine, Yonsei University College of Medicine;

<sup>2</sup>Severance Institute for Vascular and Metabolic Research, Yonsei University College of Medicine, Seoul, Korea;

<sup>3</sup>Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

**Objectives:** Serum uric acid levels have been reported to be associated with a variety of cardiovascular conditions. However, the direct association between uric acid levels and metabolic syndrome remains controversial. Thus, we evaluated the association of serum uric acid levels and metabolic syndrome in a community-based cohort study in Korea.

**Methods:** We performed cross-sectional analysis of baseline data of 889 males and 1491 females (aged 38 to 87) who participated in baseline examinations of the Korean Genome and Epidemiology Study: Kanghwa study. Blood samples were collected after at least an 8 hour fast. Uric acid quartiles were defined as follows: <4.8, 4.8-<5.6, 5.6-<6.5, ≥6.5 mg/dL in males; and <3.8, 3.8-<4.3, 4.3-<5.1, ≥5.1 mg/dL in females. Metabolic syndrome was defined by the National Cholesterol Education Program Adult Treatment Panel III Criteria with adjusted waist circumference cutoffs (90 cm for males; 80 cm for females). The association between serum uric acid quartiles and metabolic syndrome was assessed using multivariate logistic regression.

**Results:** The odds ratio for having metabolic syndrome in the highest versus lowest quartiles of serum uric acid levels was 2.67 (95% confidence interval [CI], 1.60 to 4.46) in males and 2.14 (95% CI, 1.50 to 3.05) in females after adjusting for age, smoking, alcohol intake, body mass index, total cholesterol, HbA1c, albumin,  $\gamma$ -glutamyltransferase, blood urea nitrogen, and log C-reactive protein. The number of metabolic abnormalities also increased gradually with increasing serum uric acid levels (adjusted *p* for trend <0.001 in both sexes).

**Conclusions:** Higher serum uric acid levels are positively associated with the presence of metabolic syndrome in Korean males and females.

**Key words:** Uric acid, Metabolic syndrome X, Inflammation  
*J Prev Med Public Health* 2012;45(3):181-187

## INTRODUCTION

The relationship between serum uric acid levels and a variety of cardiovascular conditions have been reported since the early 1960s [1]. Metabolic syndrome is defined by a clustering of risk factors for cardiovascular disease [2,3]. An increasing prevalence of metabolic syndrome has been reported in Korea [4,5]. The higher serum uric acid level of hyperuricemia has been associated with metabolic syndrome in studies of health screenees [3,6-9] and in nationwide surveys [10,11]. However, the direct association between uric acid levels and metabolic syndrome remains controversial, and most clinical guidelines do not recommend treating asymptomatic hyperuricemia [12]. Moreover, serum uric acid levels within a normal to high range have not been fully evaluated in association with metabolic syndrome. Therefore, we evaluated the association of serum uric

acid levels with metabolic syndrome in a rural population in Korea.

## METHODS

### I. Participants

This study is a cross-sectional analysis of baseline data of a community-based prospective cohort, which started in 2006 on Kanghwa Island, South Korea. This analysis enrolled participants who attended a health examination in 2008 or 2009 because serum uric acid testing has been available since 2008. Among the initial total of 2396 participants, we excluded 8 participants because their uric acid levels were not measured. An additional 8 participants were excluded for the following reasons: absence of systolic blood pressure (SBP) or <60 mmHg,

**Table 1.** Characteristics of the participants according to serum uric acid level

Variables	Serum uric acid quartile (mg/dL)				p-value
	<4.8 (n=197)	4.8-<5.6 (n=225)	5.6-<6.5 (n=230)	≥ 6.5 (n=237)	
<b>Male (n=889)</b>					
Age (y)	61.1 ± 7.9	59.3 ± 8.3	58.8 ± 7.5	58.4 ± 8.5	0.003
Body mass index (kg/m <sup>2</sup> )	23.8 ± 3.0	24.0 ± 2.7	24.7 ± 2.7	25.3 ± 2.9	<0.001
Waist circumference (cm)	85.6 ± 7.8	86.2 ± 7.4	87.5 ± 6.8	89.1 ± 7.2	<0.001
SBP (mmHg)	120.7 ± 16.6	122.6 ± 15.3	121.3 ± 16.1	123.3 ± 17.0	0.32
DBP (mmHg)	75.1 ± 9.3	77.0 ± 9.4	77.8 ± 9.7	78.6 ± 9.1	0.001
Total protein (g/dL)	7.4 ± 0.4	7.4 ± 0.4	7.5 ± 0.4	7.6 ± 0.4	<0.001
Albumin (g/dL)	4.4 ± 0.3	4.5 ± 0.2	4.5 ± 0.2	4.5 ± 0.3	0.008
Aspartate aminotransferase (IU/L)	25.9 ± 11.1	27.0 ± 15.4	26.5 ± 8.6	29.5 ± 14.4	0.02
Alanine transaminase (IU/L)	25.3 ± 14.6	27.0 ± 23.6	27.3 ± 13.2	30.1 ± 17.3	0.04
γ-glutamyltransferase (IU/L)	44.0 ± 65.6	42.1 ± 85.2	41.5 ± 42.7	60.3 ± 86.9	0.01
Total bilirubin (mg/dL)	0.94 ± 0.33	0.97 ± 0.35	0.96 ± 0.38	0.97 ± 0.39	0.89
Blood urea nitrogen (mg/dL)	16.3 ± 4.0	16.4 ± 4.7	16.6 ± 4.3	17.2 ± 5.0	0.13
Creatinine (mg/dL)	0.99 ± 0.12	1.02 ± 0.12	1.05 ± 0.13	1.11 ± 0.24	<0.001
HDL cholesterol (mg/dL)	43.1 ± 10.8	42.9 ± 9.8	42.4 ± 9.8	40.4 ± 9.2	0.003
Total cholesterol (mg/dL)	189.0 ± 32.8	190.1 ± 31.9	194.6 ± 34.2	189.5 ± 33.8	0.25
Triglycerides (mg/dL)	140.2 ± 110.9	157.0 ± 119.5	159.0 ± 90.1	198.7 ± 139.5	<0.001
Fasting glucose (mg/dL)	101.8 ± 27.1	98.2 ± 20.5	96.7 ± 18.4	99.1 ± 19.1	0.12
HbA1c (%)	5.8 ± 1.1	5.7 ± 0.8	5.6 ± 0.8	5.7 ± 0.8	0.10
Insulin (uIU/mL)	7.6 ± 3.1	8.0 ± 3.5	8.1 ± 3.3	8.6 ± 3.2	0.02
C-reactive protein (mg/dL)	1.9 ± 5.1	1.6 ± 5.0	1.6 ± 3.6	1.6 ± 2.9	0.91
Smoking status					
Non-smoker	144 (73.10)	163 (72.44)	166 (72.17)	180 (75.95)	0.78 <sup>1</sup>
Current smoker	53 (26.90)	62 (27.56)	64 (27.83)	57 (24.05)	
Drinking status					
Non-drinker	105 (53.30)	87 (38.67)	89 (38.70)	72 (30.38)	0.001 <sup>1</sup>
Current drinker	92 (46.70)	138 (61.33)	141 (61.30)	165 (69.62)	
Variables	Serum uric acid quartile (mg/dL)				p-value
	<3.8 (n=368)	3.8-<4.3 (n=327)	4.3-<5.1 (n=414)	≥ 5.1 (n=382)	
<b>Female (n=1491)</b>					
Age (y)	56.3 ± 8.1	56.1 ± 8.1	57.2 ± 8.0	59.0 ± 8.0	<0.001
Body mass index (kg/m <sup>2</sup> )	23.9 ± 3.0	24.5 ± 2.9	24.9 ± 3.3	25.9 ± 3.5	<0.001
Waist circumference (cm)	85.4 ± 8.9	87.0 ± 8.0	87.9 ± 7.9	90.1 ± 8.7	<0.001
SBP (mmHg)	118.4 ± 17.7	118.1 ± 16.7	119.8 ± 16.7	123.1 ± 18.6	<0.001
DBP (mmHg)	70.2 ± 10.1	71.3 ± 9.2	72.1 ± 9.8	73.0 ± 9.6	0.001
Total protein (g/dL)	7.4 ± 0.4	7.4 ± 0.4	7.5 ± 0.4	7.5 ± 0.4	<0.001
Albumin (g/dL)	4.5 ± 0.2	4.5 ± 0.2	4.5 ± 0.2	4.5 ± 0.2	0.01
Aspartate aminotransferase (IU/L)	22.8 ± 7.7	22.3 ± 5.9	23.5 ± 6.4	24.4 ± 8.2	0.001
Alanine transaminase (IU/L)	20.3 ± 11.9	19.5 ± 8.2	21.2 ± 9.5	23.2 ± 12.2	<0.001
γ-glutamyltransferase (IU/L)	18.6 ± 22.2	17.5 ± 13.5	20.7 ± 36.6	27.2 ± 58.6	0.002
Total bilirubin (mg/dL)	0.84 ± 0.30	0.83 ± 0.30	0.83 ± 0.43	0.80 ± 0.28	0.30
Blood urea nitrogen (mg/dL)	14.5 ± 3.9	15.2 ± 3.9	15.2 ± 4.2	16.3 ± 4.4	<0.001
Creatinine (mg/dL)	0.82 ± 0.10	0.83 ± 0.09	0.85 ± 0.09	0.92 ± 0.16	<0.001
HDL cholesterol (mg/dL)	47.2 ± 10.7	46.0 ± 10.4	44.1 ± 9.9	43.1 ± 9.9	<0.001
Total cholesterol (mg/dL)	199.6 ± 37.2	197.8 ± 32.7	202.0 ± 34.2	206.8 ± 39.1	0.006
Triglycerides (mg/dL)	121.8 ± 72.0	121.1 ± 59.3	145.2 ± 82.8	166.0 ± 89.7	<0.001
Fasting glucose (mg/dL)	94.0 ± 24.3	94.7 ± 18.2	95.9 ± 16.8	97.7 ± 27.9	0.11
HbA1c (%)	5.6 ± 0.8	5.6 ± 0.9	5.7 ± 0.7	5.9 ± 1.0	<0.001
Insulin (uIU/mL)	8.2 ± 3.0	8.4 ± 3.4	8.8 ± 3.5	9.6 ± 3.9	<0.001
C-reactive protein (mg/dL)	1.3 ± 3.8	1.2 ± 4.2	1.4 ± 2.4	1.8 ± 2.4	0.10
Smoking status					
Non-smoker	363 (98.64)	324 (99.08)	408 (98.55)	368 (96.34)	0.03 <sup>1</sup>
Current smoker	5 (1.36)	3 (0.92)	6 (1.45)	14 (3.66)	
Drinking status					
Non-drinker	274 (74.46)	253 (77.37)	310 (74.88)	281 (73.56)	0.69 <sup>1</sup>
Current drinker	94 (25.54)	74 (22.63)	104 (25.12)	101 (26.44)	

Data were expressed as mean ± SD or number (%).

SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein.

<sup>1</sup> Chi-squared test.

absence of diastolic blood pressure (DBP) or <40 mmHg, absence of pulse rates or >700 beats/min or <30 beats/min, and triglycerides >1500 mg/dL. A final total of 2380 participants (male 889, female 1491) were enrolled in this study. All participants signed written informed consent forms, and the Institutional Review Board approved the study protocol.

## II. Definition of Metabolic Syndrome

Metabolic syndrome was determined according to the criteria of the National Cholesterol Education Program Adult Treatment Panel III, except for waist circumference, where the Asian cutoffs were used. Thus, metabolic syndrome was defined as the presence of three or more of the following five criteria: 1) waist circumference  $\geq$  90 cm in males and  $\geq$  80 cm in females, 2) triglycerides  $\geq$  150 mg/dL or under treatment for elevated triglycerides, 3) high-density lipoprotein (HDL)-cholesterol <40 mg/dL in males and <50 mg/dL in females or under treatment for reduced HDL, 4) SBP  $\geq$  130 mmHg or DBP  $\geq$  85 mmHg or under treatment for hypertension, and 5) fasting glucose  $\geq$  100 mg/dL or under treatment for elevated glucose [13].

## III. Measuring Study Variables

Detailed methods for the measurements used in the Korean Genome and Epidemiology Study: Kanghwa study were previously reported elsewhere [14-16]. Trained personnel measured the anthropometric variables according to the written protocol. Waist circumference was measured on a horizontal plane midway between the inferior margin of the ribs and the superior border of the iliac crest using a tape measure (SECA-200; SECA, Hamburg, Germany). Resting blood pressure was measured twice with at least 5 minute intervals using an automatic sphygmomanometer (Dinamap 1846 SX/P; GE Healthcare, Waukesha, WI, USA). If the difference between the first and second measurement was more than 10 mmHg, then repeated measurements were performed. The average of the last two measurements was used for the analysis. Blood samples were collected from the antecubital vein after at least an 8 hour fast. Enzymatic methods were applied to measure fasting plasma glucose, serum uric acid, triglycerides, total cholesterol, and HDL cholesterol (ADVIA 1650; Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA). Serum uric acid levels were divided into separate quartiles for males and females. Sex-specific serum uric acid quartiles were used as

follows: <4.8, 4.8-<5.6, 5.6-<6.5,  $\geq$ 6.5 mg/dL in males; and <3.8, 3.8-<4.3, 4.3-<5.1,  $\geq$ 5.1 mg/dL in females.

## IV. Statistical Analysis

Prior to performing statistical analysis, the levels of triglycerides, fasting glucose, and C-reactive protein were log-transformed because of the skewed distribution. The differences between the investigated variables' means according to sex-specific serum uric acid quartiles were tested using the chi-squared test and analysis of variance. The relationships between serum uric acid levels and other variables were assessed using the Pearson's correlation coefficients. The trend test was performed to determine the trends with the number of metabolic abnormalities and prevalence of metabolic syndrome according to the serum uric acid quartile. The association between the sex-specific serum uric acid quartile and metabolic syndrome were tested using multivariate logistic regression analysis. We calculated the unadjusted and adjusted odds ratios (ORs) using the lowest quartile as the reference. In the adjusted model, we controlled age, smoking status (current smoker vs. others), alcohol intake (current drinker vs. others), body mass index (BMI), total cholesterol, HbA1c, albumin, blood urea nitrogen (BUN),  $\gamma$ -glutamyltransferase, and log C-reactive protein. Controlled variables were selected based on the following criteria. Age, smoking status, alcohol intake, and BMI were first selected after the literature had been reviewed, whereas sex was stratified. The variables that did not exceed 0.3 of the correlation *p*-value were then contained, after which the stepwise method was used. BUN was then additionally adjusted as a marker of kidney function. All statistical analyses were performed using SAS version 9.2.0 (SAS Inc., Cary, NC, USA). We used a two-tailed test, and a value of *p*<0.05 was considered to be statistically significant.

## RESULTS

The characteristics of the study participants are summarized in Table 1 according to the sex-specific quartile of the serum uric acid levels. The age distribution was different for males and females. The higher quartiles of serum uric acid levels tended to be associated with younger ages in males, but older ages in females.

**Table 2.** Correlation between serum uric acid and investigated variables

Variables	Male		Female	
	Pearson's coefficients	<i>p</i> -value	Pearson's coefficients	<i>p</i> -value
Age (y)	-0.096	0.004	0.138	<0.001
Body mass index (kg/m <sup>2</sup> )	0.189	<0.001	0.226	<0.001
Waist circumference (cm)	0.163	<0.001	0.207	<0.001
SBP (mmHg)	0.086	0.01	0.053	0.04
DBP (mmHg)	0.005	0.95	0.083	0.14
Total protein (g/dL)	0.192	<0.001	0.155	<0.001
Albumin (g/dL)	0.086	0.01	0.069	0.008
Aspartate aminotransferase (IU/L)	0.116	0.001	0.102	<0.001
Alanine transaminase (IU/L)	0.104	0.002	0.113	<0.001
$\gamma$ -glutamyltransferase (IU/L)	0.095	0.005	0.134	<0.001
Total bilirubin (mg/dL)	0.050	0.14	-0.046	0.07
Blood urea nitrogen (mg/dL)	0.103	0.002	0.181	<0.001
Creatinine (mg/dL)	0.323	<0.001	0.349	<0.001
Total cholesterol (mg/dL)	0.001	0.98	0.102	<0.001
HDL-cholesterol (mg/dL)	-0.119	<0.001	-0.154	<0.001
Log (triglycerides in mg/dL)	0.217	<0.001	0.252	<0.001
Log (fasting glucose in mg/dL)	-0.039	0.25	0.070	0.007
HbA1c (%)	-0.052	0.12	0.101	<0.001
Insulin (uIU/mL)	0.107	0.001	0.164	<0.001
Log (C-reactive protein in mg/L)	0.102	0.002	0.239	<0.001

SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein.

## I. Relationship Between Serum Uric Acid Level and Investigated Variables

Serum uric acid levels had positive correlations with waist circumference, BMI, SBP, total protein, albumin, aspartate aminotransferase, alanine aminotransferase,  $\gamma$ -glutamyltransferase, BUN, creatinine, log triglycerides, fasting insulin, and log C-reactive protein and an inverse correlation with HDL-cholesterol level in both sexes (Table 2). Age was negatively correlated with serum uric acid in males, but positively correlated in females. The pulse rate was positively correlated with serum uric acid in males (coefficient 0.087, *p*-value 0.010). However, total cholesterol, fasting glucose, and HbA1c were positively correlated with serum uric acid in females.

## II. Association Between Serum Uric Acid Quartiles and Metabolic Syndrome

The number of metabolic abnormalities according to the serum uric acid quartile is shown in Figure 1. The number of metabolic syndrome components increased gradually with increasing serum uric acid quartile before (*p* for trend <0.001 in both sexes) and after adjustment (*p* for trend <0.001 in both sexes). The prevalence of metabolic syndrome also increased gradually with an increasing serum uric acid quartile before (*p* for trend <0.001 in both sexes) and after adjustment (*p* for trend <0.001 in both sexes) in Figure 2.

The highest quartile had a higher OR for metabolic

**Table 3.** The association between serum uric acid level quartiles and metabolic syndrome


Serum uric acid quartile (mg/dL)	Odds ratio (95% confidence interval) for metabolic syndrome	
	Unadjusted	Adjusted <sup>1</sup>
<b>Male</b>		
1st (<4.8)	1.00	1.00
2nd (4.8-<5.6)	1.38 (0.91, 2.09)	1.72 (1.03, 2.88)
3rd (5.6-<6.5)	1.70 (1.13, 2.56)	1.94 (1.17, 3.22)
4th ( $\geq$ 6.5)	2.67 (1.78, 4.00)	2.67 (1.60, 4.46)
<b>Female</b>		
1st (<3.8)	1.00	1.00
2nd (3.8-<4.3)	0.99 (0.73, 1.34)	0.86 (0.61, 1.23)
3rd (4.3-<5.1)	2.00 (1.50, 2.66)	1.62 (1.16, 2.25)
4th ( $\geq$ 5.1)	3.32 (2.46, 4.48)	2.14 (1.50, 3.05)

<sup>1</sup> Adjusted for age, smoking, alcohol intake, body mass index, total cholesterol, HbA1c, albumin,  $\gamma$ -glutamyltransferase, blood urea nitrogen, and C-reactive protein (log-transformed).

syndrome than the lowest quartile after adjusting for age, smoking, alcohol intake, BMI, total cholesterol, HbA1c, albumin, BUN,  $\gamma$ -glutamyltransferase, and log C-reactive protein in both sexes (Table 3). Presence of metabolic syndrome significantly increased in the second, third, and fourth quartiles of serum uric acid levels in males, but at the third and fourth quartiles of serum uric acid levels in females.

## DISCUSSION


We evaluated the associations of serum uric acid levels with metabolic syndrome in a rural population in Korea.



**Figure 1.** The number of metabolic abnormalities according to the serum uric acid quartile.

<sup>1</sup> Adjusted for age, smoking, alcohol intake, body mass index, total cholesterol, HbA1c, albumin, blood urea nitrogen,  $\gamma$ -glutamyltransferase, and log CRP.

<sup>2</sup> Number of following metabolic abnormalities: 1) waist circumference  $\geq 90$  cm in male and  $\geq 80$  cm in female, 2) triglycerides  $\geq 150$  mg/dL or under treatment for elevated triglycerides, 3) high-density lipoprotein (HDL)-cholesterol  $< 40$  mg/dL in male and  $< 50$  mg/dL in female or under treatment for reduced HDL, 4) SBP  $\geq 130$  mmHg or DBP  $\geq 85$  mmHg or under treatment for hypertension, 5) fasting glucose  $\geq 100$  mg/dL or under.



**Figure 2.** Prevalence of metabolic syndrome according to the serum uric acid quartile

<sup>1</sup> Adjusted for age, smoking, alcohol intake, body mass index, total cholesterol, HbA1c, albumin, blood urea nitrogen,  $\gamma$ -glutamyltransferase, and log CRP.

We found that higher serum uric acid levels, even within the normal ranges, were associated with an increased prevalence of metabolic syndrome in both sexes even after adjusting for confounding factors.

Uric acid is the final product of purine metabolism and is excreted via the urine in higher primates [17,18]. Particularly in humans, over half of the antioxidant capacity of blood plasma comes from uric acid [18]. Reports have shown that serum uric acid levels have been increasing since 1960s in the US population, and this is possibly associated with the cardiovascular

disease epidemic that has occurred over the last 100 years [19]. There is increasing evidence that uric acid plays a role in the development of metabolic syndrome. Animal studies have shown that decreasing uric acid levels may prevent or reverse the course of metabolic syndrome. One of the possible biological mechanisms is related to insulin-stimulated endothelial nitric oxide synthesis. Insulin-stimulated endothelial nitric oxide synthase (eNOS) regulates blood flow, influencing glucose uptake in skeletal muscle [1]. Animal studies have also shown that hyperuricemia caused by eNOS,

and impaired eNOS, are associated with metabolic syndrome [1,20,21]. Another study showed that treatment for hyperuricemia patients improved endothelial dysfunction [1,22]. Therefore, we suggest that hyperuricemia could induce endothelial cell dysfunction and contribute to the development of metabolic syndrome. Another possible mechanism is related to inflammation and oxidative stress. Uric acid in adipocytes of obese mice induced inflammatory oxidative changes: hence the resulting development of metabolic syndrome [23-25].

Our findings are, in general, consistent with previous reports [3,6-11], but can be distinguished from them. First, our study population consisted of community-dwellers rather than institutionalized patients or health screenees, thereby potentially reducing selection bias.

Second, our study showed that higher serum uric acid levels, even within the normal ranges, were associated with metabolic syndrome. Serum uric acid levels ranged from 0.6 to 10.8 mg/dL in our participants. Most previous studies have investigated the association between frank hyperuricemia (defined as more than 6 mg/dL in females and more than 7 mg/dL in males) [1,9,10,26-28] with metabolic syndrome. Third, we investigated the association between serum uric acid level and metabolic syndrome in males and females separately, and the strength of association differed between sexes (Table 3). Fasting glucose and HbA1c were positively correlated with serum uric acid only in females, but not in males (Table 2). We cannot clearly explain these differences by sex; however, one of the possible explanations for the differences might be a non-linear relationship between uric acid level and glucose metabolism. Serum uric acid levels have different distributions in males and females. The range of the second quartile in males (4.8-<5.6 mg/dL) is similar to that of the third quartile in females (4.3-<5.1 mg/dL). Moreover, there might be different distributions of serum uric acid levels for men and women with diabetes, prediabetes, and using anti-diabetic medication. If serum uric acid levels have non-linear relationships with diabetes or metabolic syndrome, then the direction and strength of association could be different for males and females. A previous study reported an inverse U-shaped association between fasting glucose and uric acid levels; fasting glucose levels lower than 8.0 mmol/L were positively associated with uric acid, but glucose levels higher than 8.0 mmol/L were inversely associated [29].

Because this study is limited due to its cross-sectional nature, we could not assess temporal relationships. It is also possible that residual or unmeasured confounding

variables may exist. Some information was unavailable from the data used in this study, such as history of gout or kidney diseases, which might have influenced the serum uric acid levels. Therefore, we adjusted for BUN as an alternative marker of kidney function. However, further prospective investigations are required to fully understand the causal relationship between serum uric acid levels and the development of metabolic syndrome.

Our results suggest that individuals with high normal uric acid levels or asymptomatic hyperuricemia are at risk of metabolic syndrome. Intensive lifestyle modifications may be required for such individuals. Currently, most health screening examinations include a serum uric acid test, but physicians do not pay attention to uric acid levels unless the screenees have symptoms of gout. Physicians should explain the risks of metabolic syndrome or cardiovascular disease to individuals with high uric acid levels and recommend lifestyle modifications or consider preventive medical intervention.

In conclusion, higher serum uric acid levels are positively associated with the presence of metabolic syndrome in Korean males and females.

## ACKNOWLEDGEMENTS

This study was supported by a grant of the Korea Centers for Disease Control and Prevention (2008-E71004-00, 2009-E71006-00) and the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A102065).

## CONFLICT OF INTEREST

The authors have no conflicts of interest with the material presented in this paper.

## REFERENCES

1. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. *N Engl J Med* 2008;359(17):1811-1821.
2. Kim HC, Kang DR, Choi KS, Nam CM, Thomas GN, Suh I. Spousal concordance of metabolic syndrome in 3141 Korean couples: a nationwide survey. *Ann Epidemiol* 2006;16(4):292-298.
3. Oh HJ, Moon SH, Lee JW, Hyun HY, Lee DC, Lee HR. Relationship between serum uric acid and metabolic syndrome. *J Korean Acad Fam Med* 2006;27(9):699-705 (Korean).
4. Lim S, Park KS, Lee HK, Cho SI; Korean National Health

- and Nutrition Examination Surveys. Changes in the characteristics of metabolic syndrome in Korea over the period 1998-2001 as determined by Korean National Health and Nutrition Examination Surveys. *Diabetes Care* 2005;28(7):1810-1812.
5. Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, et al. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. *Diabetes Care* 2011; 34(6):1323-1328.
  6. Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. *Arterioscler Thromb Vasc Biol* 2005;25(5):1038-1044.
  7. Lim JH, Kim YK, Kim YS, Na SH, Rhee MY, Lee MM. Relationship between serum uric acid levels, metabolic syndrome, and arterial stiffness in Korean. *Korean Circ J* 2010;40(7):314-320.
  8. Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome. *J Chin Med Assoc* 2006;69(11):512-516.
  9. Kim SK, Park HA, Nam OY, Beck SH, Whang DH, Hwang UK, et al. Risk of the metabolic syndrome according to the level of the uric acid. *J Korean Acad Fam Med* 2007;28(6): 428-435 (Korean).
  10. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. *Am J Med* 2007;120(5): 442-447.
  11. Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, Sari I, et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. *Am J Hypertens* 2006;19(10):1055-1062.
  12. Longo DL, Kasper DL, Braunwald E, Fauci AS, Harrison TR, Hauser SL, et al. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill Medical; 2008, p. 2447.
  13. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005;112(17):2735-2752.
  14. Lee JY, Ahn SV, Choi DP, Suh M, Kim HC, Kim YS, et al. Association between hypertension and pulmonary function in rural adults in Korea. *J Prev Med Public Health* 2009;42(1):21-28 (Korean).
  15. Oh SM, Kim HC, Ahn SV, Chi HJ, Suh I. Association between meat consumption and carotid intima-media thickness in Korean adults with metabolic syndrome. *J Prev Med Public Health* 2010;43(6):486-495.
  16. Suh M, Lee JY, Ahn SV, Kim HC, Suh I. C-reactive protein and carotid intima-media thickness in a population of middle-aged Koreans. *J Prev Med Public Health* 2009; 42(1):29-34 (Korean).
  17. Kang DH. Potential role of uric acid as a risk factor for cardiovascular disease. *Korean J Intern Med* 2010;25(1): 18-20.
  18. Wikipedia. Uric acid [cited 2011 Mar 4]. Available from: [http://en.wikipedia.org/wiki/Uric\\_acid](http://en.wikipedia.org/wiki/Uric_acid).
  19. Glynn RJ, Campion EW, Silbert JE. Trends in serum uric acid levels 1961-1980. *Arthritis Rheum* 1983;26(1):87-93.
  20. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. *Kidney Int* 2005;67(5):1739-1742.
  21. Cook S, Hugli O, Egli M, Vollenweider P, Burcelin R, Nicod P, et al. Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. *Swiss Med Wkly* 2003;133(25-26):360-363.
  22. Mercurio G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. *Am J Cardiol* 2004;94(7):932-935.
  23. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. *Am J Physiol Cell Physiol* 2007;293(2):C584-C596.
  24. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. *J Clin Invest* 2004;114(12):1752-1761.
  25. Cheung KJ, Tzameli I, Pissios P, Rovira I, Gavrillova O, Ohtsubo T, et al. Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. *Cell Metab* 2007; 5(2):115-128.
  26. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. *Hypertension* 2003;42(3):247-252.
  27. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. *Arch Intern Med* 2004; 164(14):1546-1551.
  28. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. *Nat Clin Pract Nephrol* 2005;1(2):80-86.
  29. Cook DG, Shaper AG, Thelle DS, Whitehead TP. Serum uric acid, serum glucose and diabetes: relationships in a population study. *Postgrad Med J* 1986;62(733):1001-1006.